Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Allergan settles Alzheimer's therapy lawsuit for $750 million

(Reuters) - Allergan Plc would pay $750 million to settle a class action lawsuit from a group of direct purchasers of Alzheimer’s disease therapy Namenda, the drugmaker said, in a resolution to the litigation that was set to face trial on Monday.


The settlement makes no admission of wrongdoing on its part and will be recorded as a charge to its third-quarter earnings, the company said.

The lawsuit alleged that Allergan’s Forest units worked to delay generic competition for Namenda, including entering an illegal agreement with its competitor Mylan NV.

Forest, the original maker of Namenda, discontinued the tablets taken twice daily in February 2014 and replaced it with a version taken once daily before the launch of a generic version in July 2015.

Days later, Allergan, then called Actavis PLC, announced its acquisition of Forest.

The plaintiff claimed that the plan to drop the older version caused patients to switch to the newer version in advance, forcing them to pay for Namenda for patients who would otherwise be taking the generic version.

The drug was first approved by the U.S. health regulator in 2003 for the treatment of moderate to severe dementia related to the memory-robbing disease.

OCTOBER 28, 2019


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies